Vanessa Evans

PhD (Immunology)

Research skills

  • Technical
    FACS staining, FACSCalibur, LSRII, Primary Cell Culture, Dendritic cell isolation, Thymus, Miltenyi AutoMACS, Primary cell sorting, HIV, Transfection, Virus Production, Flow Cytometry, PBMC isolation, Cytokine bead arrays, Microarray
  • IT
    Microsoft Word, Microsoft Excel, Microsoft PowerPoint, GraphPad Prism

Research interests

  • Interests
    Dendritic Cell, HIV, HIV Immunology, Persistence

Awards & achievements

  • Nov 2011
    Grant: amfAR - American Foundation for AIDS Research - The role of dendritic cells in HIV latency
  • Feb 2011
    Award: Lorne Infection and Immunity Poster Award, Lorne, Australia
  • Jan 2011
    Award: Monash PhD Symposium Oral Presentation Award, Melbourne, Australia
  • Dec 2010
    Scholarship: HIV DART Conference, Los Cabos, Mexico
  • Jul 2010
    Scholarship: International AIDS Society Conference, Vienna, Austria
  • Jun 2008
    Award: Aust. Centre for HIV and Hepatitis Student Gold Medal (best oral presentation), Barossa, Australia
  • Mar 2008
    Scholarship: Keystone Symposium (HIV pathogenesis), Banff, Canada
  • Jan 2008
    Scholarship: Monash Postgraduate Scholarship
  • Jul 2007
    Scholarship: International AIDS Society Conference, Sydney, Australia
  • Mar 2007
    Scholarship: Keystone Symposium (HIV pathogenesis)
  • Feb 2006
    Scholarship: Monash Departmental Scholarship

Other

  • Languages
    English

Publications

  • Finding a cure for HIV: will it ever be achievable?

    Sharon R Lewin, Vanessa A Evans, Julian H Elliott, Bruno Spire, Nicolas Chomont

    Journal of the International AIDS Society. 01/2011; 14:4.

    Combination antiretroviral therapy (cART) has led to a major reduction in HIV-related mortality and morbidity. However, HIV still cannot be cured. With the absence of an effective prophylactic or therapeutic vaccine, increasing numbers of infected people, emerging new toxicities secondary to cART an... [more] Combination antiretroviral therapy (cART) has led to a major reduction in HIV-related mortality and morbidity. However, HIV still cannot be cured. With the absence of an effective prophylactic or therapeutic vaccine, increasing numbers of infected people, emerging new toxicities secondary to cART and the need for life-long treatment, there is now a real urgency to find a cure for HIV.There are currently multiple barriers to curing HIV. The most significant barrier is the establishment of a latent or "silent" infection in resting CD4+ T cells. In latent HIV infection, the virus is able to integrate into the host cell genome, but does not proceed to active replication. As a consequence, antiviral agents, as well as the immune system, are unable to eliminate these long-lived, latently infected cells. Reactivation of latently infected resting CD4+ T cells can then re-establish infection once cART is stopped. Other significant barriers to cure include residual viral replication in patients receiving cART, even when the virus is not detectable by conventional assays. In addition, HIV can be sequestered in anatomical reservoirs, such as the brain, gastrointestinal tract and genitourinary tract.Achieving either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells) remains a major challenge. Several studies have now demonstrated that treatment intensification appears to have little impact on latent reservoirs. Some potential and promising approaches that may reduce the latent reservoir include very early initiation of cART and the use of agents that could potentially reverse latent infection.Agents that reverse latent infection will promote viral production; however, simultaneous administration of cART will prevent subsequent rounds of viral replication. Such drugs as histone deacetylase inhibitors, currently used and licensed for the treatment of some cancers, or activating latently infected resting cells with cytokines, such as IL-7 or prostratin, show promising results in reversing latency in vitro when used either alone or in combination. In order to move forward toward clinical trials that target eradication, there needs to be careful consideration of the risks and benefits of these approaches, agreement on the most informative endpoints for eradication studies and greater engagement of the infected community.
  • 4.11
    Impact points
    Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro.

    Vanessa A Evans, Luxshimi Lal, Ramesh Akkina, Ajantha Solomon, Edwina Wright, Sharon R Lewin, Paul U Cameron

    Retrovirology. 01/2011; 8:43.

    HIV-1 infection of the thymus contributes to the defective regeneration and loss of CD4+ T cells in HIV-1-infected individuals. As thymic dendritic cells (DC) are permissive to infection by HIV-1, we examined the ability of thymic DC to enhance infection of thymocytes which may contribute to the ove... [more] HIV-1 infection of the thymus contributes to the defective regeneration and loss of CD4+ T cells in HIV-1-infected individuals. As thymic dendritic cells (DC) are permissive to infection by HIV-1, we examined the ability of thymic DC to enhance infection of thymocytes which may contribute to the overall depletion of CD4+ T cells. We compared productive infection in isolated human thymic and blood CD11c+ myeloid DC (mDC) and CD123+ plasmacytoid DC (pDC) using enhanced green fluorescent protein (EGFP) CCR5 (R5)-tropic NL(AD8) and CXCR4 (X4)-tropic NL4-3 HIV-1 reporter viruses. Transfer of productive HIV-1 infection from thymic mDC and pDC was determined by culturing these DC subsets either alone or with sorted thymocytes. Productive infection was observed in both thymic pDC and mDC following exposure to R5 HIV-1 and X4 HIV-1. Thymic pDC were more frequently productively infected by both R5 and X4 HIV-1 than thymic mDC (p = 0.03; n = 6). Thymic pDC efficiently transferred productive R5 HIV-1 infection to both CD3(hi) (p = 0.01; mean fold increase of 6.5; n = 6) and CD3(lo) thymocytes (mean fold increase of 1.6; n = 2). In comparison, transfer of productive infection by thymic mDC was not observed for either X4 or R5 HIV-1. The capacity of thymic pDC to efficiently transfer R5 HIV-1 to both mature and immature thymocytes that are otherwise refractory to R5 virus may represent a pathway to early infection and impaired production of thymocytes and CD4+ T cells in HIV-1-infected individuals.
  • 9.43
    Impact points
    Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

    Paul U Cameron, Suha Saleh, Georgina Sallmann, Ajantha Solomon, Fiona Wightman, Vanessa A Evans, Genevieve Boucher, Elias K Haddad, Rafick-Pierre Sekaly, Andrew N Harman, Jenny L Anderson, Kate L Jones, Johnson Mak, Anthony L Cunningham, Anthony Jaworowski, Sharon R Lewin

    Proceedings of the National Academy of Sciences of the United States of America. 09/2010; 107(39):16934-9.

    Eradication of HIV-1 with highly active antiretroviral therapy (HAART) is not possible due to the persistence of long-lived, latently infected resting memory CD4(+) T cells. We now show that HIV-1 latency can be established in resting CD4(+) T cells infected with HIV-1 after exposure to ligands for ... [more] Eradication of HIV-1 with highly active antiretroviral therapy (HAART) is not possible due to the persistence of long-lived, latently infected resting memory CD4(+) T cells. We now show that HIV-1 latency can be established in resting CD4(+) T cells infected with HIV-1 after exposure to ligands for CCR7 (CCL19), CXCR3 (CXCL9 and CXCL10), and CCR6 (CCL20) but not in unactivated CD4(+) T cells. The mechanism did not involve cell activation or significant changes in gene expression, but was associated with rapid dephosphorylation of cofilin and changes in filamentous actin. Incubation with chemokine before infection led to efficient HIV-1 nuclear localization and integration and this was inhibited by the actin stabilizer jasplakinolide. We propose a unique pathway for establishment of latency by direct HIV-1 infection of resting CD4(+) T cells during normal chemokine-directed recirculation of CD4(+) T cells between blood and tissue.
  • 6.89
    Impact points
    Genetic modulation of TLR8 response following bacterial phagocytosis.

    Michael P Gantier, Aaron T Irving, Maria Kaparakis-Liaskos, Dakang Xu, Vanessa A Evans, Paul U Cameron, James A Bourne, Richard L Ferrero, Matthias John, Mark A Behlke, Bryan R G Williams

    Human mutation. 09/2010; 31(9):1069-79.

    Human Toll-like receptors (TLRs) TLR7, TLR8, and TLR9 are important immune sensors of foreign nucleic acids encountered by phagocytes. Although there is growing evidence implicating TLR7 and TLR9 in the detection of intracellular pathogenic bacteria, characterization of such a role for TLR8 is curre... [more] Human Toll-like receptors (TLRs) TLR7, TLR8, and TLR9 are important immune sensors of foreign nucleic acids encountered by phagocytes. Although there is growing evidence implicating TLR7 and TLR9 in the detection of intracellular pathogenic bacteria, characterization of such a role for TLR8 is currently lacking. A recent genetic study has correlated the presence of a TLR8 single nucleotide polymorphism (SNP) (rs3764880:A>G; p.Met1Val) with the development of active tuberculosis, suggesting a role for TLR8 in the detection of phagosomal bacteria. Here we provide the first direct evidence that TLR8 sensing is activated in human monocytic cells following Helicobacter pylori phagocytosis. In addition, we show that rs3764880 fine tunes translation of the two TLR8 main isoforms, without affecting protein function. Although we show that TLR8 variant 2 (TLR8v2) is the prevalent form of TLR8 contributing to TLR8 function, we also uncover a role for the TLR8 long isoform (TLR8v1) in the positive regulation of TLR8 function in CD16(+)CD14(+) differentiated monocytes. Thus, TLR8 sensing can be activated following bacterial phagocytosis, and rs3764880 may play a role in the modulation of TLR8-dependent microbicidal response of infected macrophages.
  • 3.86
    Impact points
    Human thymic dendritic cells: regulators of T cell development in health and HIV-1 infection.

    Vanessa A Evans, Paul U Cameron, Sharon R Lewin

    Clinical immunology (Orlando, Fla.). 02/2008; 126(1):1-12.

    Thymic dendritic cells (DCs) are a unique subset of bone marrow-derived professional antigen presenting cells (APCs) that interact closely with developing thymocytes and play a crucial role in the process of negative selection and subsequent deletion of potential auto-reactive T cell clones. HIV-1 i... [more] Thymic dendritic cells (DCs) are a unique subset of bone marrow-derived professional antigen presenting cells (APCs) that interact closely with developing thymocytes and play a crucial role in the process of negative selection and subsequent deletion of potential auto-reactive T cell clones. HIV-1 infection of the thymus has been implicated in the defective regeneration of the CD4(+) T cell pool in infected individuals. Thymic DCs are permissive to infection by HIV-1 and given their important role in T cell development, infected DCs within the thymus may contribute to the depletion of T cells. Here we review the phenotype and function of different DC subsets found within the human thymus and discuss potential mechanisms of how DCs may be important in CD4(+) T cell dysfunction in HIV-1 infection.
  • Human thymic dendritic cells: Regulators of T cell development in health and HIV-1 infection

    Vanessa A. Evans, Paul U. Cameron, Sharon R. Lewin

    Clinical Immunology.

    Thymic dendritic cells (DCs) are a unique subset of bone marrow-derived professional antigen presenting cells (APCs) that interact closely with developing thymocytes and play a crucial role in the process of negative selection and subsequent deletion of potential auto-reactive T cell clones. HIV-1 i... [more] Thymic dendritic cells (DCs) are a unique subset of bone marrow-derived professional antigen presenting cells (APCs) that interact closely with developing thymocytes and play a crucial role in the process of negative selection and subsequent deletion of potential auto-reactive T cell clones. HIV-1 infection of the thymus has been implicated in the defective regeneration of the CD4+ T cell pool in infected individuals. Thymic DCs are permissive to infection by HIV-1 and given their important role in T cell development, infected DCs within the thymus may contribute to the depletion of T cells. Here we review the phenotype and function of different DC subsets found within the human thymus and discuss potential mechanisms of how DCs may be important in CD4+ T cell dysfunction in HIV-1 infection.
6
Publications
4
Followers
Current advisors
Sharon Lewin